50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to transform the lives of patients with rare genetic diseases using our ex vivo autologous HSC gene therapy approach.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2790% match
“Our mission is to bring innovative gene therapy products to patients living with serious, life-threatening rare diseases, and we believe our product candidates have the potential to provide long-lasting and transformative benefits to the patient communities we aim to serve.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0173% match
“Our mission is to bring life-changing therapeutics to people living with rare diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1273% match
“Our purpose is to develop and commercialize HSC gene therapies that free patients from a lifetime of genetic disease.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2372% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0172% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1872% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1272% match
“Our mission is to transform the lives of people affected by rare diseases and devastating conditions.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-02-2271% match
“Our mission is to bring to market therapies that address high unmet medical needs of patients with genetic mitochondrial diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2771% match
“Our mission is to develop innovative, transformative therapies for patients with devastating diseases through the use of our novel chRDNA genome-editing technology.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0570% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1470% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0970% match
“Our mission is to provide therapeutic relief to those suffering from debilitating rare diseases that have limited or no treatment options to help them live their best possible lives and achieve their full potential.”In use 2024 – now·1 sighting·SEC Form 20-F, filed 2024-04-3070% match
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-04-1970% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1470% match
“Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2569% match
“Our mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1269% match
“Our mission is to improve lives through the curative potential of gene therapy.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0169% match
“Our mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2469% match
“Our mission is to empower physicians globally to deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination protocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-05-1468% match
“Our mission is to deliver curative, one-time administered genomic medicines that transform the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0268% match
“Our mission is to transform the lives of patients living with devastating genetic diseases by building the leading integrated genetic medicine company focused on developing and commercializing potentially curative therapeutics based on our GeneRide platform.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-1568% match
“Our mission is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2468% match
“Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2268% match
“Our mission is to change the standard of care for patients with blood cancer by engineering hematopoietic stem cells (“HSCs”) to enable the use of targeted therapies post-transplant.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2368% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1168% match
“Our mission is to create and advance new medicines for patients suffering from serious and rare diseases that are underserved by today’s therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to transform the lives of patients with serious, rare respiratory diseases through innovative inhaled therapies, beginning with pulmonary fibrosis.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-04-3067% match
“Our mission is to develop novel therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-03-2867% match
“Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to transform the lives of patients through the creation of novel gene control medicines by building a fully integrated, leading biopharmaceutical company.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-2067% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2267% match
“Our mission is to discover, develop, and deliver novel, life-transforming therapies to people suffering from rare, severe, and devastating neuromuscular diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0367% match
“Our mission is to improve the lives of patients who suffer from rare diseases for which there are limited or no available treatments, with an initial therapeutic focus on Cirrhosis ascites, patients suffering from AIDS, Cancer and chronic pain, nausea and discomfort associated with chemotherapy and neuropathy.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-11-0667% match
“Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune diseases and cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2367% match
“Our mission is to create life-changing T cell therapies for patients with cancer and autoimmune disorders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0467% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2567% match
“Our mission is to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with SCD.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-02-2467% match
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1267% match
“Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0967% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0166% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3066% match
“Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2666% match
“Our mission is to develop and commercialize proprietary therapeutic drug products that treat rare and orphan diseases, particularly for those diseases where no approved treatment currently exists.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2666% match
“Our mission is to transform the lives of patients by creating medicines with improved therapeutic profiles for areas of unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2366% match
“Our mission is to provide superior treatment options for complex diseases and disorders to improve the lives of patients by developing innovative new medicines that exploit the unique role of NNRs.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-0666% match
“Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0466% match
“Our mission is to develop innovative therapies to address areas of high unmet medical need, initially in RASopathies for NF1.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3066% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1666% match
Showing 1–50 of 50